Dr. Ashlee Watts: Effective Therapies for Hock Lameness
Wednesday, December 7, 2016
Lexington, KY- Dr. Ashlee E. Watts was a presenter at the annual American Association of Equine Practitioners (AAEP) conference in Orlando, FL., detailing two years of clinical research results on the effects of Resveratrol and horses experiencing on hock lameness. The study titled, "A randomized, controlled trial of the effects of Resveratrol administration in performance horses with lameness localized to the distal tarsal joints," provided proof that Equithrive® Joint is effective therapy for equine hock lameness.
Watts' research has created positive buzz in the horse world among veterinarians and caregivers as research in the equine supplement market is not commonly performed due to the time and cost involved. A board certified large animal surgeon in the Department of Large Animal Clinical Sciences at Texas A&M University, Watts is also Director of the Comparative Orthopedics and Regenerative Medicine Laboratory at Texas A&M University. The study was published in the Journal of the American Veterinary Medical Association.
Dr. Watts has been a presenter at AAEP numerous times since 2007. "The AAEP Annual Convention is a great opportunity to present clinically relevant research findings to equine veterinarians. This allows practitioners to stay up-to-date on the latest innovations and discoveries that are relevant to their patients and clients."
Equithrive® is the pioneer in equine resveratrol therapy. Resveratrol has become known to the public as the healthy ingredient in red wine. Equithrive® has developed a proprietary Resveratrol product (Resverasyn®) that has been proven in multiple university studies to reduce lameness, inflammation and oxidative stress in horses. Excessive inflammation plays a major role in arthritis and in Equine Metabolic Syndrome (EMS). The company developed Equithrive® Joint to support healthy joint function in horses during aging, training and competition. Metabarol™ contains a higher dose of Resverasyn® and has been demonstrated to reduce insulin levels in EMS horses that are prone to foundering
Posted on Mar 7, 2017
Posted on Oct 27, 2017
Posted on May 15, 2017
Posted on Jul 8, 2017